BLB(SZ:002286)2019-10-30 16:00Financial Performance - Net profit attributable to shareholders was ¥15,750,723.14, representing a significant increase of 131.86% year-on-year[7]. - Operating revenue for the reporting period was ¥443,163,275.38, reflecting a growth of 1.49% compared to the same period last year[7]. - The company's total equity increased to CNY 1,545,785,169.76 from CNY 1,506,890,879.13, showing a growth of 2.6%[36]. - The company reported a decrease in inventory to CNY 197,376,670.31 from CNY 220,819,612.62, a decline of about 10.6%[28]. - The total profit for Q3 2019 was CNY 47,542,002.31, compared to CNY 51,964,241.58 in the previous year, reflecting a decline of approximately 8.5%[48]. - The company's operating profit for Q3 2019 was CNY 47,467,960.65, a decrease from CNY 50,975,722.01 in Q3 2018, showing a reduction of about 6.1%[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,580,424,891.25, a slight increase of 0.05% compared to the end of the previous year[7]. - The company's total liabilities decreased to CNY 1,007,879,004.93 from CNY 1,037,268,673.40, a reduction of about 2.8%[30]. - The company's current assets totaled CNY 994,227,921.38, up from CNY 926,552,404.40 at the end of 2018, indicating a growth of approximately 7.3%[29]. - Total liabilities decreased to CNY 1,095,370,339.29 from CNY 1,173,043,163.06, reflecting a decline of about 6.6%[35]. - The company's total liabilities reached CNY 1,037,268,673.40, with non-current liabilities at CNY 52,750,001.27[65]. Cash Flow - The net cash flow from operating activities was ¥95,399,177.34, showing a decrease of 25.50% year-to-date[7]. - Cash inflow from investment activities was ¥12,835,018.92, significantly lower than ¥344,084,989.44 in the previous year, leading to a net cash outflow of ¥75,113,288.56[56]. - The cash flow from investment activities showed a net inflow of ¥11,971,049.06, contrasting with a net outflow of -¥208,452,728.94 in the previous year[59]. - The company experienced a net decrease in cash and cash equivalents of -¥126,520,612.45 in Q3 2019, compared to an increase of ¥10,853,665.48 in Q3 2018[56]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,584[11]. - The company terminated the acquisition of 2,000,000,000 shares of China Regenerative Medicine International Limited, which represented 11.37% of the total issued shares, with a target price of HKD 360 million (HKD 0.18 per share) due to temporary financial difficulties faced by the seller[18]. Investment and Expenses - Investment income decreased by 71.41% year-on-year, attributed to reduced financial management income and lower investment returns from joint ventures[16]. - Research and development expenses for Q3 2019 were CNY 831,253.81, down from CNY 1,850,222.47 in Q3 2018, indicating a decrease of 55.1%[38]. - The company reported an investment income of CNY 1,448,595.78, significantly up from CNY 426,594.06 in the previous year, an increase of 239.5%[39]. - The financial expenses for Q3 2019 were CNY 17,476,336.51, an increase from CNY 13,476,245.59 in Q3 2018, representing a rise of about 29.5%[51]. Overall Financial Health - The weighted average return on net assets was 1.01%, an increase from 0.57% in the previous year[7]. - The company's equity attributable to shareholders increased to CNY 1,572,545,886.32 from CNY 1,540,019,868.57, showing a growth of approximately 2.1%[31]. - The total comprehensive income for the third quarter was CNY 20.74 million, compared to CNY 4.48 million in the previous year[44].